Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/17496
Título
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Autor(es)
Garcia-Donas, Jesus | Esteban, Emilio | Leandro-García, Luis Javier | Castellano, Daniel E | González del Alba, Aranzazu | Climent, Miguel Angel | Arranz, José Angel | Gallardo, Enrique | Puente, Javier | Bellmunt, Joaquim | Mellado, Begoña | Martínez, Esther | Moreno, Fernando | Font, Albert | Robledo Batanero, Mercedes CNIO | Rodriguez Antona, Cristina CNIO
Fecha de publicación
2011-11
Cita
Lancet Oncol . 2011;12(12):1143-50
Idioma
Inglés
Tipo de documento
journal article
Resumen
BACKGROUND
Sunitinib is a tyrosine kinase inhibitor with proven efficacy in renal-cell carcinoma, but some patients do not respond or need dose reductions due to toxicity. Because there are no validated molecular predictors of response or toxicity to sunitinib, we aimed to identify genetic markers predictive of outcome and toxic effects.
METHODS
In our observational, prospective study we enrolled previously untreated adults (≥ 18 years) with clear-cell renal-cell carcinoma at 15 institutions in the Spanish Oncology Genitourinary Group in Spain. Patients received sunitinib according to local practice guidelines. We assessed RECIST response, progression-free survival (PFS), overall survival, and toxicity of sunitinib with 16 key polymorphisms in nine genes: VEGFR2 (rs2305948 and rs1870377), VEGFR3 (rs307826, rs448012, and rs307821), PDGFR-α (rs35597368), VEGF-A (rs2010963, rs699947, and rs1570360), IL8 (rs1126647), CYP3A4 (rs2740574), CYP3A5 (rs776746), ABCB1 (rs1045642, rs1128503, and rs2032582), and ABCB2 (rs2231142). We assessed associations with efficacy and toxicity by use of univariable and multivariable analyses (with clinical factors associated with outcomes as covariates). We adjusted for multiplicity using the Bonferroni method; p values of less than 0·0031 before adjustment were deemed to still be significant after adjustment.
FINDINGS
We enrolled 101 patients between Oct 10, 2007, and Dec 13, 2010. 95 of these patients were included in toxicity analyses and 89 in the efficacy analyses. Two VEGFR3 missense polymorphisms were associated with reduced PFS with sunitinib on multivariable analysis: rs307826 (hazard ratio [HR] per allele 3·57, 1·75-7·30; p(unadjusted)=0·00049, p(adjusted)=0·0079) and rs307821 (3·31, 1·64-6·68; p(unadjusted)=0·00085, p(adjusted)=0·014). The CYP3A5*1 (rs776746) high metabolising allele was associated in a multivariable analysis with an increased risk of dose reductions due to toxicity (HR per allele 3·75, 1·67-8·41; p(unadjusted)=0·0014, p(adjusted)=0·022). No other SNPs were associated with sunitinib response or toxicity.
INTERPRETATION
Polymorphisms in VEGFR3 and CYP3A5*1 might be able to define a subset of patients with renal-cell carcinoma with decreased sunitinib response and tolerability. If confirmed, these results should promote interventional studies testing alternative therapeutic approaches for patients with such variants.
FUNDING
Pfizer.
MESH
Polymorphism, Single Nucleotide | Aged | Antineoplastic Agents | Carcinoma, Renal Cell | Cytochrome P-450 CYP3A | Disease-Free Survival | Female | Gene Frequency | Genetic Predisposition to Disease | Heterozygote | Homozygote | Humans | Indoles | Kaplan-Meier Estimate | Kidney Neoplasms | Logistic Models | Male | Middle Aged | Patient Selection | Phenotype | Precision Medicine | Predictive Value of Tests | Proportional Hazards Models | Prospective Studies | Protein Kinase Inhibitors | Pyrroles | Risk Assessment | Risk Factors | Spain | Sunitinib | Time Factors | Treatment Outcome | Vascular Endothelial Growth Factor Receptor-3
Versión en línea
DOI
Aparece en las colecciones
Ficheros en el ítem
![Acceso Abierto Acceso Abierto](/themes/Mirage2/images/openAccess.png)
- Nombre:
- T3_1_version aceptada.docx
- Tamaño:
- 33.73Kb
- Formato:
- Microsoft Word 2007
- Descripción:
- Carátula postprint
![Acceso Abierto Acceso Abierto](/themes/Mirage2/images/openAccess.png)
- Nombre:
- Singlenucleotidepolymorphismas ...
- Tamaño:
- 242.2Kb
- Formato:
- Descripción:
- Preprint